Sector: Healthcare | Industry: Pharmaceuticals |
Company Contact | |
Address: | 26 Henlow Bay WINNIPEG MB R3Y 1G4 |
Tel: | N/A |
Website: | N/A |
IR: | N/A |
Key People | ||
N/A |
Business Overview |
Cytophage Technologies Ltd. is a Canadian biotechnology company. The Company uses advanced molecular genetic techniques and synthetic biology to create bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria, the Company generates customized phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a phage-display methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health. Its products include FarmPhage, AviPhage, PhageFend, and BoviPhage. FarmPhage is a water-soluble phage solution for livestock. AviPhage is poultry health products offered by the Company. |
Financial Overview |
For the fiscal year ended 31 December 2023, Cytophage Technologies Ltd revenues was not reported. Net loss increased 26% to C$4.6M. Higher net loss reflects Share-based payments increase of 83% to C$821K (expense), Professional fees increase from C$194K to C$518K (expense), Depreciation increase of 41% to C$513K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -C$0.44 to -C$0.55. |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $29.16M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$4.53M as of Dec 31, 2023 |
Net annual income (TTM): | -$4.64M as of Dec 31, 2023 |
Free cash flow (TTM): | -$3.02M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $1.77M as of Dec 31, 2023 |
Shares outstanding: | 8,444,316 as of Dec 31, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |